Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

GISELLE S MOSNAIM

Allopathic & Osteopathic Physicians Allergy & Immunology

NPI
1679501571
CMS profile
1236302
Location
CHICAGO, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$94,781.58

103 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 3 of 3; records 101–103 of 103 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

GISELLE S MOSNAIM

NPI 1679501571 · CMS profile ID 1236302

Allopathic & Osteopathic Physicians / Allergy & Immunology

CHICAGO, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–103 of 103 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1679501571?year=2024&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
GISELLE S MOSNAIM, NPI 1679501571, CMS profile ID 1236302. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–103 of 103 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1679501571?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). GISELLE S MOSNAIM, NPI 1679501571, CMS profile ID 1236302. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–103 of 103 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1679501571?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
GISELLE S MOSNAIM, NPI 1679501571, CMS profile ID 1236302, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–103 of 103 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1679501571?year=2024&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

103 matching records · $94,781.58 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 103 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–103 of 103.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Genentech USA, Inc. $0.9802/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133015302 CMS
Chiesi USA, Inc. $53.1702/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151814296 CMS
Chiesi USA, Inc. $623.2902/15/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151814301 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,327.56 3
PY2020 $1,978.66 2
PY2022 $6,750.00 2
PY2023 $55,244.37 45
PY2024 $94,781.58 103
PY2025 $170,387.74 146

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $35,771.82 43
PY2025 Principal investigator $909,194.22 238
PY2024 Recipient $23,163.27 26
PY2024 Principal investigator $414,530.15 204
PY2023 Recipient $17,436.76 27
PY2023 Principal investigator $294,538.05 51
PY2022 Recipient $2,476.90 9
PY2022 Principal investigator $162,081.35 19
PY2021 Principal investigator $61,839.98 38
PY2020 Principal investigator $12,250.00 2
PY2019 Principal investigator $34,701.24 19

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

281 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $489.11 12/24/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133353
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $489.11 12/24/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133355
Principal investigator 1 GENZYME CORPORATION $2,600.00 12/22/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226140652
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,804.96 12/17/2025 Covered Recipient Teaching Hospital
Skokie Hospital
A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, safety, and tolerability of remibrutinib (LOU064) in Chronic Inducible Urticaria (CINDU) in adults inadequately co No dispute reported 06/30/2026 1190294606
Principal investigator 1 Novartis Pharmaceuticals Corporation $10,616.04 12/17/2025 Non-covered Recipient Entity
ENDEAVOR HEALTH
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista No dispute reported 06/30/2026 1190301459
Recipient Novartis Pharmaceuticals Corporation $1,954.96 12/12/2025 Covered Recipient Physician Research Publication/ Writing Support No dispute reported 06/30/2026 1190293314
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,736.12 12/04/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE No dispute reported 06/30/2026 1184133347
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,483.37 12/04/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE No dispute reported 06/30/2026 1184133349
Principal investigator 1 Novartis Pharmaceuticals Corporation $31,787.00 12/01/2025 Covered Recipient Teaching Hospital
Skokie Hospital
A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal and Open-label Extension Study Followed by Long-term Open-label Treatment Cycles to Assess the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Chronic Spontaneous U No dispute reported 06/30/2026 1190298057
Principal investigator 1 GlaxoSmithKline, LLC. $2,030.00 11/24/2025 Non-covered Recipient Entity
ENDEAVOR HEALTH
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192142363
Principal investigator 1 GlaxoSmithKline, LLC. $3,000.00 11/24/2025 Non-covered Recipient Entity
ENDEAVOR HEALTH
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192142383
Principal investigator 1 GlaxoSmithKline, LLC. $6,094.44 11/21/2025 Non-covered Recipient Entity
ENDEAVOR HEALTH
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192145065
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,500.00 11/14/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE No dispute reported 06/30/2026 1184133341
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,580.00 11/14/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE No dispute reported 06/30/2026 1184133343
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 11/14/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE No dispute reported 06/30/2026 1184133345
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,438.98 10/29/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE No dispute reported 06/30/2026 1184133339
Principal investigator 1 GlaxoSmithKline, LLC. $10,381.14 10/23/2025 Non-covered Recipient Entity
ENDEAVOR HEALTH
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192136304
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,483.37 10/23/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE No dispute reported 06/30/2026 1184133337
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,736.12 10/16/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE No dispute reported 06/30/2026 1184133335
Principal investigator 1 Novartis Pharmaceuticals Corporation $269.76 10/08/2025 Covered Recipient Teaching Hospital
Skokie Hospital
A double-blind, randomized, placebo-controlled trial to evaluate the efficacy, pharmacokinetics and safety of remibrutinib (LOU064) for 24 weeks in adolescents from 12 to less than 18 years of age with chronic spontaneous urticaria inadequately controlled No dispute reported 06/30/2026 1190298061
Principal investigator 1 Novartis Pharmaceuticals Corporation $32,146.03 10/08/2025 Covered Recipient Teaching Hospital
Skokie Hospital
A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, safety, and tolerability of remibrutinib (LOU064) in Chronic Inducible Urticaria (CINDU) in adults inadequately co No dispute reported 06/30/2026 1190298065
Recipient GENZYME CORPORATION $500.00 09/30/2025 Covered Recipient Physician A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Persistent Asthma No dispute reported 06/30/2026 1226119002
Recipient GENZYME CORPORATION $250.00 09/30/2025 Covered Recipient Physician A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Persistent Asthma No dispute reported 06/30/2026 1226119010
Recipient GENZYME CORPORATION $500.00 09/29/2025 Covered Recipient Physician A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Persistent Asthma No dispute reported 06/30/2026 1226119020
Recipient GENZYME CORPORATION $250.00 09/28/2025 Covered Recipient Physician A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Persistent Asthma No dispute reported 06/30/2026 1226119006
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,722.98 09/23/2025 Covered Recipient Teaching Hospital
Skokie Hospital
A Multicenter, Open-label Phase 3 Study: Ambulatory Blood Pressure Monitoring in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Treated With Remibrutinib up to 12 Weeks No dispute reported 06/30/2026 1190294599
Principal investigator 1 Genentech, Inc. $26,676.00 09/18/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
RO IIS 2022 21359 No dispute reported 06/30/2026 1211551330
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,506.58 09/17/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244047265
Principal investigator 1 GENZYME CORPORATION $1,875.00 09/15/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226140544
Principal investigator 1 GlaxoSmithKline, LLC. $5,521.30 09/12/2025 Non-covered Recipient Entity
ENDEAVOR HEALTH
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192142390
Principal investigator 1 GlaxoSmithKline, LLC. $500.00 09/12/2025 Non-covered Recipient Entity
ENDEAVOR HEALTH
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192142416
Principal investigator 1 GlaxoSmithKline, LLC. $17,642.00 09/04/2025 Non-covered Recipient Entity
ENDEAVOR HEALTH
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192136310
Principal investigator 1 GlaxoSmithKline, LLC. $500.00 09/03/2025 Non-covered Recipient Entity
ENDEAVOR HEALTH
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192136298
Recipient Regeneron Pharmaceuticals, Inc. $638.44 09/01/2025 Covered Recipient Physician REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184120791
Principal investigator 1 AstraZeneca UK Limited $18,275.00 08/28/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
a phase two a,randomized,double blind,placebo controlled study to assess efficacy and safety of atuliflapon given orally once daily for twelve weeks in adults with moderate to severe uncontrolled asthma No dispute reported 06/30/2026 1185541690
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $590.00 08/21/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244047263
Principal investigator 1 GlaxoSmithKline, LLC. $15,700.00 08/12/2025 Non-covered Recipient Entity
ENDEAVOR HEALTH CLINICAL OPERATIONS -
A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT No dispute reported 06/30/2026 1192136279
Principal investigator 1 GlaxoSmithKline, LLC. $500.00 08/12/2025 Non-covered Recipient Entity
ENDEAVOR HEALTH CLINICAL OPERATIONS -
A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT No dispute reported 06/30/2026 1192145078
Principal investigator 1 Genentech, Inc. $1,100.00 08/07/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
RO IIS 2022 21359 No dispute reported 06/30/2026 1211551357
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $489.11 07/30/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133331
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $489.11 07/30/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133333
Principal investigator 1 Genentech, Inc. $26,676.00 07/29/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
RO IIS 2022 21359 No dispute reported 06/30/2026 1211551343
Principal investigator 1 Genentech, Inc. $26,676.00 07/29/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
RO IIS 2022 21359 No dispute reported 06/30/2026 1211551347
Principal investigator 1 Genentech, Inc. $26,676.00 07/22/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
RO IIS 2022 21359 No dispute reported 06/30/2026 1211551338
Principal investigator 1 GlaxoSmithKline, LLC. $7,677.18 07/22/2025 Non-covered Recipient Entity
ENDEAVOR HEALTH CLINICAL OPERATIONS -
A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT No dispute reported 06/30/2026 1192136289
Principal investigator 1 ARS Pharmaceuticals Operations, Inc. $19,850.00 07/17/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
FREQUENT URTICARIA FLARES IN PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA (EPI U02) (THE STUDY) No dispute reported 06/30/2026 1245870866
Principal investigator 1 ARS Pharmaceuticals Operations, Inc. $3,000.00 07/17/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
FREQUENT URTICARIA FLARES IN PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA (EPI U02) (THE STUDY) No dispute reported 06/30/2026 1245870869
Principal investigator 1 Novartis Pharmaceuticals Corporation $84,322.50 07/15/2025 Non-covered Recipient Entity
ENDEAVOR HEALTH
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista No dispute reported 06/30/2026 1190301461
Principal investigator 1 GlaxoSmithKline, LLC. $4,012.58 07/10/2025 Non-covered Recipient Entity
ENDEAVOR HEALTH CLINICAL OPERATIONS -
A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT No dispute reported 06/30/2026 1192136283
Recipient GENZYME CORPORATION $500.00 07/09/2025 Covered Recipient Physician Registry of Asthma Patients Initiating DUPIXENT (RAPID) No dispute reported 06/30/2026 1226119014
Recipient GENZYME CORPORATION $250.00 07/09/2025 Covered Recipient Physician Registry of Asthma Patients Initiating DUPIXENT (RAPID) No dispute reported 06/30/2026 1226119018
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $489.11 07/02/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133311
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $489.11 07/02/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133313
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $489.11 07/02/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133315
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $489.11 07/02/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133317
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $489.11 07/02/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133319
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $489.11 07/02/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133321
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,535.00 07/02/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184133323
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,000.00 07/02/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184133325
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 07/02/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184133327
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,500.00 07/02/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184133329
Recipient Regeneron Pharmaceuticals, Inc. $1,447.80 07/01/2025 Covered Recipient Physician REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184120789
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 06/30/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184133307
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $250.00 06/25/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133303
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $250.00 06/25/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133305
Principal investigator 1 GlaxoSmithKline, LLC. $700.15 06/16/2025 Non-covered Recipient Entity
ENDEAVOR HEALTH
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192142402
Recipient GENZYME CORPORATION $250.00 06/13/2025 Covered Recipient Physician Registry of Asthma Patients Initiating DUPIXENT (RAPID) No dispute reported 06/30/2026 1226118978
Recipient GENZYME CORPORATION $500.00 06/13/2025 Covered Recipient Physician Registry of Asthma Patients Initiating DUPIXENT (RAPID) No dispute reported 06/30/2026 1226118982
Recipient GENZYME CORPORATION $250.00 06/13/2025 Covered Recipient Physician Registry of Asthma Patients Initiating DUPIXENT (RAPID) No dispute reported 06/30/2026 1226118986
Recipient GENZYME CORPORATION $500.00 06/13/2025 Covered Recipient Physician Registry of Asthma Patients Initiating DUPIXENT (RAPID) No dispute reported 06/30/2026 1226118990
Recipient GENZYME CORPORATION $250.00 06/13/2025 Covered Recipient Physician Registry of Asthma Patients Initiating DUPIXENT (RAPID) No dispute reported 06/30/2026 1226118994
Recipient GENZYME CORPORATION $500.00 06/13/2025 Covered Recipient Physician Registry of Asthma Patients Initiating DUPIXENT (RAPID) No dispute reported 06/30/2026 1226118998
Recipient Regeneron Pharmaceuticals, Inc. $592.50 06/01/2025 Covered Recipient Physician REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184120781
Recipient Regeneron Pharmaceuticals, Inc. $1,135.00 06/01/2025 Covered Recipient Physician REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184120783
Recipient Regeneron Pharmaceuticals, Inc. $915.26 06/01/2025 Covered Recipient Physician REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184120785
Recipient Regeneron Pharmaceuticals, Inc. $1,459.29 06/01/2025 Covered Recipient Physician REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184120787
Recipient F. Hoffmann-La Roche AG $1,863.75 05/29/2025 Covered Recipient Physician A Phase III Trial of Xolair in CIU No dispute reported 06/30/2026 1211535878
Recipient F. Hoffmann-La Roche AG $1,863.75 05/29/2025 Covered Recipient Physician A Phase III Trial of Xolair in CIU No dispute reported 06/30/2026 1211535883
Recipient F. Hoffmann-La Roche AG $1,491.00 05/29/2025 Covered Recipient Physician Matched-Adjusted Indirect Comparison Analysis Demonstrating Significantly Better Improvement in Patient-Reported Outcomes for Omalizumab vs Dupilumab at 12 Weeks in Patients With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1211535887
Principal investigator 1 Genentech, Inc. $53,352.00 05/29/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
RO IIS 2022 21359 No dispute reported 06/30/2026 1211551334
Principal investigator 1 Incyte Corporation $10,477.00 05/22/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240486579
Recipient GENZYME CORPORATION $250.00 05/18/2025 Covered Recipient Physician Registry of Asthma Patients Initiating DUPIXENT (RAPID) No dispute reported 06/30/2026 1226118974
Recipient GENZYME CORPORATION $500.00 05/16/2025 Covered Recipient Physician Registry of Asthma Patients Initiating DUPIXENT (RAPID) No dispute reported 06/30/2026 1226118954
Recipient GENZYME CORPORATION $250.00 05/14/2025 Covered Recipient Physician Registry of Asthma Patients Initiating DUPIXENT (RAPID) No dispute reported 06/30/2026 1226118958
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $68.20 05/14/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244047271
Recipient GENZYME CORPORATION $250.00 05/13/2025 Covered Recipient Physician Registry of Asthma Patients Initiating DUPIXENT (RAPID) No dispute reported 06/30/2026 1226118961
Recipient GENZYME CORPORATION $500.00 05/13/2025 Covered Recipient Physician Registry of Asthma Patients Initiating DUPIXENT (RAPID) No dispute reported 06/30/2026 1226118964
Recipient GENZYME CORPORATION $500.00 05/13/2025 Covered Recipient Physician Registry of Asthma Patients Initiating DUPIXENT (RAPID) No dispute reported 06/30/2026 1226118969
Principal investigator 1 GlaxoSmithKline, LLC. $2,735.05 05/05/2025 Non-covered Recipient Entity
ENDEAVOR HEALTH
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192142408
Recipient Regeneron Pharmaceuticals, Inc. $1,135.00 05/01/2025 Covered Recipient Physician REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184120775
Recipient Regeneron Pharmaceuticals, Inc. $1,067.80 05/01/2025 Covered Recipient Physician REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184120777
Recipient Regeneron Pharmaceuticals, Inc. $1,067.80 05/01/2025 Covered Recipient Physician REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184120779
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $489.11 04/30/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133267
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $489.11 04/30/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133269
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $489.11 04/30/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133271
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $489.11 04/30/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133273
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $489.11 04/30/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133275
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $489.11 04/30/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133277
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $489.11 04/30/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133279
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $489.11 04/30/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133281
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $489.11 04/30/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133283
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $489.11 04/30/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133285
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $489.11 04/30/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133287
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $489.11 04/30/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133289
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $489.11 04/30/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133291
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $489.11 04/30/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133293
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $489.11 04/30/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133295
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $489.11 04/30/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133297
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $489.11 04/30/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133299
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,281.62 04/24/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244047261
Principal investigator 1 Novartis Pharmaceuticals Corporation $76,620.16 04/15/2025 Non-covered Recipient Entity
ENDEAVOR HEALTH
A 12-week randomized, participant and investigator-blinded, placebo-controlled, exploratory study in adult participants with Chronic Urticaria to assess the Efficacy and Safety and explore the Mechanism of Action of remibrutinib (LOU064) No dispute reported 06/30/2026 1190301463
Principal investigator 1 Incyte Corporation $3,250.00 04/10/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240486569
Principal investigator 1 GlaxoSmithKline, LLC. $1,033.60 04/04/2025 Non-covered Recipient Entity
ENDEAVOR HEALTH
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192142371
Recipient Regeneron Pharmaceuticals, Inc. $309.38 04/01/2025 Covered Recipient Physician REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184120767
Recipient Regeneron Pharmaceuticals, Inc. $416.67 04/01/2025 Covered Recipient Physician REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184120769
Recipient Regeneron Pharmaceuticals, Inc. $60.00 04/01/2025 Covered Recipient Physician DUPIXENT CLINICAL DEVELOPMENT PROGRAM No dispute reported 06/30/2026 1184120771
Recipient Regeneron Pharmaceuticals, Inc. $416.67 04/01/2025 Covered Recipient Physician REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184120773
Recipient Novartis Pharma AG $4,337.00 03/20/2025 Covered Recipient Physician CLOU064A2301,CLOU064A2302 No dispute reported 06/30/2026 1248109281
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,134.90 03/20/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244047259
Principal investigator 1 Genentech, Inc. $26,676.00 03/15/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
RO IIS 2022 21359 No dispute reported 06/30/2026 1211551351
Principal investigator 1 Genentech, Inc. $3,300.00 03/15/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
RO IIS 2022 21359 No dispute reported 06/30/2026 1211551355
Principal investigator 1 GlaxoSmithKline, LLC. $841.00 03/07/2025 Non-covered Recipient Entity
ENDEAVOR HEALTH
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192136316
Principal investigator 1 GlaxoSmithKline, LLC. $737.00 03/07/2025 Non-covered Recipient Entity
ENDEAVOR HEALTH
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192136328
Principal investigator 1 GlaxoSmithKline, LLC. $2,226.00 03/07/2025 Non-covered Recipient Entity
ENDEAVOR HEALTH
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192142396
Recipient Novartis Pharmaceuticals Corporation $4,602.13 03/02/2025 Covered Recipient Physician CLOU064A2201,CLOU064A2301,CLOU064A2302 No dispute reported 06/30/2026 1190292406
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,126.52 02/27/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244047257
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $204.60 02/21/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244047269
Principal investigator 1 Novartis Pharmaceuticals Corporation $28,914.58 02/13/2025 Non-covered Recipient Entity
NORTHSHORE UNIVERSITY HEALTH SYSTEM NORTHSHORE UNIVERSITY HEALTH SYSTEM RESEARCH INSTITUTE
A double-blind, randomized, placebo-controlled trial to evaluate the efficacy, pharmacokinetics and safety of remibrutinib (LOU064) for 24 weeks in adolescents from 12 to less than 18 years of age with chronic spontaneous urticaria inadequately controlled No dispute reported 06/30/2026 1190300579
Principal investigator 1 GlaxoSmithKline, LLC. $1,522.00 02/07/2025 Non-covered Recipient Entity
ENDEAVOR HEALTH
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192136321
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $489.11 02/03/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133253
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $489.11 02/03/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133255
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $489.11 02/03/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133257
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $489.11 02/03/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133259
Recipient Regeneron Pharmaceuticals, Inc. $353.57 02/01/2025 Covered Recipient Physician REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184120755
Recipient Regeneron Pharmaceuticals, Inc. $353.57 02/01/2025 Covered Recipient Physician REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184120757
Recipient Regeneron Pharmaceuticals, Inc. $416.67 02/01/2025 Covered Recipient Physician REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184120759
Recipient Regeneron Pharmaceuticals, Inc. $353.57 02/01/2025 Covered Recipient Physician REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184120761
Recipient Regeneron Pharmaceuticals, Inc. $353.57 02/01/2025 Covered Recipient Physician REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184120763
Recipient Regeneron Pharmaceuticals, Inc. $416.67 02/01/2025 Covered Recipient Physician REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184120765
Principal investigator 1 Novartis Pharmaceuticals Corporation $52,699.63 01/30/2025 Non-covered Recipient Entity
NORTHSHORE UNIVERSITY HEALTH SYSTEM NORTHSHORE UNIVERSITY HEALTH SYSTEM RESEARCH INSTITUTE
A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, safety, and tolerability of remibrutinib (LOU064) in Chronic Inducible Urticaria (CINDU) in adults inadequately co No dispute reported 06/30/2026 1190300583
Principal investigator 1 Novartis Pharmaceuticals Corporation $12,500.02 01/28/2025 Non-covered Recipient Entity
NORTHSHORE UNIVERSITY HEALTH SYSTEM NORTHSHORE UNIVERSITY HEALTH SYSTEM RESEARCH INSTITUTE
A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal and Open-label Extension Study Followed by Long-term Open-label Treatment Cycles to Assess the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Chronic Spontaneous U No dispute reported 06/30/2026 1190300577
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,966.70 01/16/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244047255
Principal investigator 1 GlaxoSmithKline, LLC. $1,679.60 01/13/2025 Non-covered Recipient Entity
ENDEAVOR HEALTH
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192142376
Principal investigator 1 Incyte Corporation $6.60 01/09/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240486471
Principal investigator 1 Incyte Corporation $60.58 01/09/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240486476
Principal investigator 1 Incyte Corporation $32.32 01/09/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240486481
Principal investigator 1 Incyte Corporation $9.18 01/09/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240486487
Principal investigator 1 Incyte Corporation $6.00 01/09/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240486494
Principal investigator 1 Incyte Corporation $4.32 01/09/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240486500
Principal investigator 1 Incyte Corporation $9.32 01/09/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240486506
Principal investigator 1 Incyte Corporation $52.48 01/09/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240486511
Principal investigator 1 Incyte Corporation $74.64 01/09/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240486517
Principal investigator 1 Incyte Corporation $205.26 01/09/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240486522
Principal investigator 1 Incyte Corporation $5.40 01/09/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240486528
Principal investigator 1 Incyte Corporation $4.66 01/09/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240486533
Principal investigator 1 Incyte Corporation $4.66 01/09/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240486538
Principal investigator 1 Incyte Corporation $1.20 01/09/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240486544
Principal investigator 1 Incyte Corporation $16.16 01/09/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240486552
Principal investigator 1 Incyte Corporation $8.64 01/09/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240486558
Principal investigator 1 Incyte Corporation $9.32 01/09/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240486565
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.00 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133014
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.00 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133016
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $89.10 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133018
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $35.64 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133020
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.00 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133022
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.00 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133024
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.00 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133026
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $26.40 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133028
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $66.00 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133030
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.00 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133032
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $26.40 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133034
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $89.10 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133036
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $35.64 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133038
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.00 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133040
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133042
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.00 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133044
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.00 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133046
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.00 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133048
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.00 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133050
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $66.00 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133052
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.00 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133054
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $26.40 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133056
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $89.10 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133058
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $26.40 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133060
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $66.00 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133062
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.00 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133064
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $26.40 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133066
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $89.10 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133068
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.00 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133070
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $66.00 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133072
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.00 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133074
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $26.40 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133076
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $89.10 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133078
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.00 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133080
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $26.40 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133082
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $26.40 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133084
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $26.40 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133086
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $89.10 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133088
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.00 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133090
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $66.00 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133092
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $66.00 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133094
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.00 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133096
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $26.40 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133098
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $26.40 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133100
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $89.10 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133102
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.00 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133104
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $66.00 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133106
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.00 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133108
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $26.40 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133110
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $89.10 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133112
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.00 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133114
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $66.00 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133116
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.00 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133118
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $26.40 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133120
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $89.10 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133122
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.00 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133124
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.00 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133126
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.00 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133128
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $66.00 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133130
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.00 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133132
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133134
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $66.00 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133136
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.00 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133138
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $250.00 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133140
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $26.40 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133142
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $89.10 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133144
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.00 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133146
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $89.10 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133148
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.00 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133150
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $66.00 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133152
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.00 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133154
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $26.40 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133156
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $89.10 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133158
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.00 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133160
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.00 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133162
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.00 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133164
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $26.40 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133166
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $66.00 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133168
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.00 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133170
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $89.10 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133172
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $26.40 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133174
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.00 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133176
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $66.00 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133178
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.00 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133180
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.00 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133182
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.00 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133184
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $35.64 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133186
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $89.10 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133188
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $26.40 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133190
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.00 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133192
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $66.00 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133194
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.00 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133196
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $26.40 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133198
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $89.10 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133200
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.00 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133202
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.00 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133204
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $66.00 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133206
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $26.40 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133208
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $26.40 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133210
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $89.10 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133212
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.00 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133214
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $66.00 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133216
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.00 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133219
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $26.40 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133221
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $89.10 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133223
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.00 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133225
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.00 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133227
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.00 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133229
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $26.40 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133231
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $66.00 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133233
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.00 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133235
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $26.40 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133237
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $89.10 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133239
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.00 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133241
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.00 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133243
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.00 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133245
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $26.40 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133247
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $66.00 01/08/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184133249
Principal investigator 1 Novartis Pharmaceuticals Corporation $43,207.89 01/01/2025 Covered Recipient Teaching Hospital
Skokie Hospital
A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal and Open-label Extension Study Followed by Long-term Open-label Treatment Cycles to Assess the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Chronic Spontaneous U No dispute reported 06/30/2026 1190294595
Principal investigator 1 Novartis Pharmaceuticals Corporation $75,725.26 01/01/2025 Covered Recipient Teaching Hospital
Skokie Hospital
A double-blind, randomized, placebo-controlled trial to evaluate the efficacy, pharmacokinetics and safety of remibrutinib (LOU064) for 24 weeks in adolescents from 12 to less than 18 years of age with chronic spontaneous urticaria inadequately controlled No dispute reported 06/30/2026 1190294602
Principal investigator 1 Novartis Pharmaceuticals Corporation $37,753.42 01/01/2025 Covered Recipient Teaching Hospital
Skokie Hospital
A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, safety, and tolerability of remibrutinib (LOU064) in Chronic Inducible Urticaria (CINDU) in adults inadequately co No dispute reported 06/30/2026 1190294609